The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+


Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

What is Neuromodulation?

Breaking News Share

Pain Management Experts Provide Perspectives on Neuromodulation

Dec. 14, 2017 - In a health awareness article that appears in the Guardian, International Neuromodulation Society President Timothy Deer, MD, describes growing excitement about neuromodulation therapy for managing symptoms of long-term disease, and new and more tailored forms of neuromodulation therapy. Due to the potential of neuromodulation to improve quality of life, he said, awareness should grow among patients and their clinicians. In the same news supplement, INS member Tacson Fernandez, MBBS, FRCA, FIPP, described a case in which spinal cord stimulation provided pain relief to a patient who had suffered brachial plexus injury in a motorcycle accident years before. (Media Planet)

Device Company Targeting Chronic Low Back Pain Passes Early Milestone of U.S. Clinical Trial

Dec. 11, 2017 - Mainstay Medical plc announced an interim analysis of the first 58 patients to complete its U.S. clinical trial showed no safety concerns with the company's implantable device for chronic low back pain. The analysis was carried out by an independent data committee that also recommended achieving a final sample size of 168 evaluable patients. The company expects to reach full enrollment by the second quarter of 2018. (Irish Times)

Technology Publication Recognizes a Company for Developing a Sacral Neuromodulation System

Dec. 11, 2017 - Axonics Modulation Technologies is one of 15 companies named a "Fierce 15" by the publication Fierce Biotech for 2017. The company is developing a rechargeable, miniaturized implantable device to provide sacral neuromodulation for overactive bladder. A U.S. clinical trial is beginning enrollment this month. (Fierce Biotech)

FDA Approves Rechargeable Deep Brain Stimulation System with Independent Current Control

Dec. 11, 2017 - Boston Scientific Corp. announced FDA approval of its deep brain stimulation system to address symptoms of Parkinson's disease with electrodes that have independent current control. U.S. approval was based on a multi-center, randomized, controlled, prospective, double-blind study of 292 Parkinson's disease patients at 23 sites in the United States. Data from the Intrepid study are expected to be released in 2018. The filing included additional safety data from an earlier study in Europe, where the rechargeable system launched in 2012. (PR Newswire)


To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM